Valuation: IN8bio, Inc.

Market Cap 14M 12.49M 11.63M 10.59M 19.94M 1.35B 20.09M 141M 54.7M 688M 52.55M 51.42M 2.21B P/E 2026 *
-1.28x
P/E 2027 * -1.49x
Enterprise Value 14M 12.49M 11.63M 10.59M 19.94M 1.35B 20.09M 141M 54.7M 688M 52.55M 51.42M 2.21B EV / Sales 2026 *
-
EV / Sales 2027 * 12.7x
Free-Float
92.42%
Yield 2026 *
-
Yield 2027 * -
1 day+1.43%
1 week+14.52%
Current month+6.77%
1 month+18.33%
6 months-1.39%
Current year-39.32%
1 week 1.31
Extreme 1.31
1.46
1 month 1.01
Extreme 1.01
1.46
Current year 0.88
Extreme 0.88
2.73
1 year 0.88
Extreme 0.88
2.73
3 years 0.88
Extreme 0.88
74.4
5 years 0.88
Extreme 0.88
282.72
10 years 0.88
Extreme 0.88
309.57
Manager TitleAgeSince
Chief Executive Officer 50 01/11/2015
Chief Tech/Sci/R&D Officer 72 01/11/2018
Director of Finance/CFO 43 08/02/2021
Director TitleAgeSince
Director/Board Member 50 01/11/2015
Director/Board Member 68 01/07/2019
Director/Board Member 64 04/08/2021
Date Insider Type Main position Quantity % Market Cap. Importance
27/05/26 Don

Director

-724,637 7.3589%
09/05/26 Free

Chairman

22,000 0.2234%
09/05/26 Free

Director

22,000 0.2234%
Change 5-day change 1-year change 3-year change Capi.($)
+1.43%+14.52%-40.59%-95.17% 14M
+4.16%+3.42%+49.37%+94.17% 74.31B
+1.82%-2.50%+21.68%+76.90% 56.95B
+2.49%+0.75%+5.60%+37.16% 48.3B
+0.50%+2.94%+344.62%+722.17% 44.51B
+3.05%-1.80%+28.78%+34.51% 43.8B
+1.00%-1.46%+5.17%+111.90% 41.12B
-0.54%+2.41%+9.31%+58.85% 31.07B
+4.51%+8.22%+37.86%+32.49% 28.97B
+0.76%-1.45%-7.44%-11.12% 24.53B
Average +1.93%+1.31%+45.44%+106.19% 39.36B
Weighted average by Cap. +2.20%-0.46%+58.92%+137.02%

Financials

2026 *2027 *
Net sales - 1.11M 987K 919K 837K 1.58M 107M 1.59M 11.11M 4.32M 54.38M 4.15M 4.06M 175M
Net income -20.96M -18.7M -17.42M -15.86M -29.86M -2.02B -30.08M -211M -81.91M -1.03B -78.7M -77M -3.31B -23.72M -21.17M -19.72M -17.94M -33.79M -2.28B -34.04M -238M -92.7M -1.17B -89.06M -87.14M -3.75B
Net Debt - -
Logo IN8bio, Inc.
IN8bio, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of gamma-delta T cell-based immunotherapies for cancer patients. Gamma-delta T cells are a specialized population of T cells that possess properties, including the ability to differentiate between healthy and diseased tissue. Its lead program, INB-100, is in an ongoing investigator-sponsored Phase I clinical trial of acute myeloid leukemia (AML). Its other product candidates include INB-200, INB-300, INB-500 and INB-600. INB-200 is a genetically modified, autologous gamma-delta T cell product to be administered in combination with the current standard-of-care chemotherapy in newly diagnosed glioblastoma (GBM). INB-300 is a preclinical program focused on developing unique non-signaling gamma-delta T cell based chimeric antigen receptor (nsCAR)-enabled DeltEx product candidates with a focus on targeting liquid tumors and extracranial solid tumors.
Employees
-
Date Price Change Volume
05/10/26 $1.420 +1.43% 107,128
02/10/26 $1.400 0.00% 39,473
01/10/26 $1.400 +5.26% 78,466
30/09/26 $1.330 +2.70% 30,299
29/09/26 $1.295 +4.44% 62,212
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
1.420USD
Average target price
7.000USD
Spread / Average Target
+392.96%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. INAB Stock